Professional Marketing briefs: March 2013

Share this article:
Geno Germano
Geno Germano

Although the FDA has input on drug names, Reuters dug into what's behind brand names starting with Xs and Zs and found it's not necessarily a trademark issue. Reuters found that X and Z are memorable and that starting a drug's name with one of these letters generally means the drug will be marketed to HCPs. Reuters added the jumble may hint at what the drug does. Example: Pfizer's drug Xeljanz works on Janus Kinase molecules.

The latest Pfizer earnings call provided insight into Pfizer's marketing push for its RA drug Xeljanz. Oncology and specialty president Geno Germano confirmed the company gave 30-day supplies to a select group of rheumatologists and reception has been positive. Germano acknowledged consumer awareness isn't high, but said a DTC campaign will roll out in the middle of this year.

A PhRMA report suggests the industry is looking at a robust pipeline. Among the trade group's findings: more than 5,000 new medications are being studied and 70% are “potential first-in-class medicines.” The interest group noted that rare diseases are garnering attention, with about 140 potential medicines being researched in the past decade.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...